Our researchers have developed commercialisation opportunities in a range of fields, including new medical treatments, diagnostic assays, and a game to aid physiotherapy and rehabilitation.
We're looking for commercial partners to take these opportunities to market.
ARU welcomes the recommendations of the Independent Review of University Spinout Companies and is actively working to integrate the best practices outlined in the Review and the USIT guide into our IP, commercialisation, and spin-out policies and procedures. We expect to complete this integration in 2025, and these practices will be adopted in the creation of all future ARU spin-out companies. The equity share between the university and founders during spin-out creation will follow the recommendations set out in the Review.
We understand the need for clear and transparent communication regarding spin-outs to researchers across all disciplines. Our aim is to raise awareness of spin-outs as a viable option for translating research into real-world applications and achieving impact. ARU seeks to ensure that spin-outs are consistently considered for the exploitation of all university intellectual property (IP).
ARU acknowledges that there is no 'one-size-fits-all' approach to spin-outs. We are incorporating this flexibility into our spin-out development processes, along with the relevant recommendations of the Review and the USIT guide. We are committed to continuous improvement and will assess the effectiveness of our internal guidelines, exploring potential refinements based on the USIT Guide on an ongoing basis. Additionally, we seek to build collaborations with other universities to share best practices.
Explore opportunities below.
A screening service available from ARU can identify anti-fibrotic activity of novel small molecules and biologicals.
We have a suite of PCR assays available for licensing. They're robust, specific, simple and sensitive assays to identify a range of common fungal and antibiotic-resistant infections.
Work with us on a cost-effective rehabilitation game that improves the range of motion and the kinematic ability of motor-impaired participants. Use for physiotherapy purposes at home or in community settings.
Our researchers have identified a potential new treatment for cancer. We're seeking a commercial partner to develop the use of sucralose as a cancer treatment.
We've identified a potential new treatment for fibrotic diseases using two generic compounds, giving the potential for a new combination therapy.
Based in ARU’s state-of-the-art Science Centre in Cambridge, ARU Biometrics apply biomedical science technologies to solve your problems. Available resources include the Applied Extracellular Vesicle Research Laboratory, Immune Checkpoint Assays, Inflammation Biology, the Platelet Function Laboratory and Workplace drug testing.
Contact our Research and Innovation Development Office to discuss these opportunities.